Diabetes mellitus. Criterios diagnósticos y clasificación. Epidemiología. Etiopatogenia. Evaluación inicial del paciente con diabetes

Referencias bibliográficas

• World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO consultation. Ginebra, WHO 1999. WHO/NCD/NCS/99.2.
• American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;Suppl1:S81-90.
• International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327-34.
• Ziemer DC, Kolm P, Weintraub WS, Vaccarino V, Rhee MK, Twombly JG, et al. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. Ann Intern Med. 2010;152:770-7.
• Nowicka P, Santoro N, Liu H, Lartaud D, Shaw MM, Goldberg R, et al. Utility of hemoglobin A1c for diagnosing prediabetes and diabetes in obese children and adolescents. Diabetes Care. 2011;34:1306-11.
• Zhang X, Gregg EW, Williamson DF, Barker LE, Thomas W, Bullard KM, et al. A1C level and future risk of diabetes: a systematic review. Dia-betes Care. 2010;33:1665-73.
• American Diabetes Association. Standards of medical care in diabetes 2016. Diabetes Care. 2016;39Suppl1:S1–S112.
• Expert Committee on the Diagnosis and Classification of Diabetes Me-llitus. Report of the Expert Committee on the Diagnosis and Classifica-tion of Diabetes Mellitus. Diabetes Care. 1997;20:1183-97.
• Lawrence JM, Contreras R, Chen W, Sacks DA. Trends in the prevalence of preexisting diabetes and gestational diabetes mellitus among a racially/ethnically diverse population of pregnant women, 1999-2005. Diabetes Care. 2008;31:899-904.
• Crowther CA, Hiller JE, Moss JR, McPhee AJ, Jeffries WS, Robinson JS; Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect of treatment of gestational diabetes melli-tus on pregnancy outcomes. N Engl J Med. 2005;352:2477-86.
• Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, Coustan DR, et al; HAPO Study Cooperative Research Group. Hyperglycemia and adverse pregnancy outcomes. N Engl J Med. 2008;358:1991-2002.
• Vandorsten JP, Dodson WC, Espeland MA, Grobman WA, Guise JM, Mercer BM, et al. NIH consensus development conference: diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements. 2013;29:1-31.
• International Association of Diabetes and Pregnancy Study Groups Consensus Panel, Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, et al; International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010;33: 676-82.
• Vandorsten JP, Dodson WC, Espeland MA, Grobman WA, Guise JM, Mercer BM, et al. NIH consensus development conference: diagnosing gestational diabetes mellitus. NIH Consens State Sci Statements. 2013;29:1-31.
• Corcoy R, Lumbreras B, Bartha JL, Ricart W, Grupo Español de Diabetes y Embarazo. Nuevos criterios diagnósticos de diabetes gestacional a partir del estudio HAPO. ¿Son válidos en nuestro me-dio? Av Diabetol. 2010;26:139-142.
• International Association of Diabetes and Pregnancy Study Groups Re-commendations on the Diagnosis and Classification of Hyperglycemia in Pregnancy. Diabetes Care. 2010;33:676-82.
• International Diabetes Federation. IDF diabetes atlas. 7ª ed. Brussels, Belgium: International Diabetes Federation; 2015.
• Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carme-na R, et al. Prevalence of diabetes mellitus and impaired glucose regula-tion in Spain: the Di@bet.es Study. Diabetologia. 2012;88-93.
• Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes worldwide. Diabe-tes Mondiale (DiaMond) Project Group. Diabetes Care. 2000; 23:1516.
• Silink M. Childhood diabetes: a global perspective. Horm Res 2002; 57 Suppl 1:1.
• Writing Group for the SEARCH for Diabetes in Youth Study Group, Dabelea D, Bell RA, et al. Incidence of diabetes in youth in the United States. JAMA. 2007;297:2716.
• Moltchanova EV, Schreier N, Lammi N, Karvonen M. Seasonal variation of diagnosis of type 1 diabetes mellitus in children worldwide. Diabet Med. 2009;26:673-8.
• Dabelea D, Mayer-Davis EJ, Saydah S, Imperatore G, Linder B, Divers J, et al. Prevalence of type 1 and type 2 diabetes among children and ado-lescents from 2001 to 2009. JAMA. 2014;311:1778.
• Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep. 2013;13:795.
• Palmer JP, Hampe CS, Chiu H, Goel A, Brooks-Worrell BM. Is latent autoimmune diabetes in adults distinct from type 1 diabetes or just type 1 diabetes at an older age? Diabetes. 2005; 54:62-7
• Redondo MJ, Fain PR, Eisenbarth GS. Genetics of type 1A dia-betes. Recent Prog Horm Res. 2001;56:69-89.
• Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med. 2009;360:1646-54.
• Pociot F, Akolkar B, Concannon P, Erlich HA, Julier C, Morahan G, et al. Genetics of type 1 diabetes: What’s next? Diabetes. 2010.59:1561-71.
• Khalil I, d’Auriol L, Gobet M, Morin L, Lepage V, Deschamps I, et al. A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest. 1990; 85:1315.
• Rowe RE, Leech NJ, Nepom GT, McCulloch DK. High genetic risk for IDDM in the Pacific Northwest. First report from the Washington State Diabetes Prediction Study. Diabetes. 1994;43:87.
• Pugliese A, Zeller M, Fernández A Jr, Zalcberg LJ, Bartlett RJ, Ricordi C, et al. The insulin gene is transcribed in the human thymus and transcrip-tion levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibilitylocus for type 1 diabetes. Nat Genet.1997;15:293-7.
• Sabater L, Ferrer-Francesch X, Sospedra M, Caro P, Juan M, Pujol-Bo-rrell R. Insulin alleles and autoimmune regulator (AIRE) gene expression both influence insulin expression in the thymus. J Autoimmun. 2005;25:312.
• Atkinson MA, Bluestone JA, Eisenbarth GS, Hebrok M, Herold KC, Accili D, et al. How does type 1 diabetes develop? The notion of homicide or b-cell suicide revisited. Diabetes. 2011;60:1370-9.
• Krishnamurthy B, Dudek NL, McKenzie MD, Purcell AW, Brooks AG, Gellert S, et al. Responses against islet antigens in NOD mice are preven-ted by tolerance to proinsulin but not IGRP. J Clin Invest. 2006;116:3258.
• Taplin CE, Barker JM. 2008. Autoantibodies in type 1 diabetes. Autoim-munity. 2008;41:11-8.
• Wong FS, Karttunen J, Dumont C, Wen L, Visintin I, Pilip IM, et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med. 1999;5:1026.
• Achenbach P, Koczwara K, Knopff A, Naserke H, Ziegler AG, Bonifacio E. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest. 2004;114:589.
• Bingley PJ. Clinical applications of diabetes antibody testing. J Clin En-docrinol Metab. 2010;95:25-33.
• Knip M, Korhonen S, Kulmala P, Veijola R, Reunanen A, Raitakari OT, et al. Prediction of type 1 diabetes in the general population. Diabetes Care. 2010;33:1206-12.
• Skyler JS. Prediction and prevention of type 1 diabetes: Progress, pro-blems, and prospects. Clin Pharmacol Ther. 2007;81:768-71.
• Fourlanos S, Harrison LC, Colman PG. The accelerator hypothesis and increasing incidence of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2008;15:321-5.
• Cooke A. Review series on helminths, immune modulation and the hygie-ne hypothesis: How might infection modulate the onset of type 1 diabe-tes? Immunology. 2009;126:12-7.
• Vaarala O, Atkinson MA, Neu J. The “perfect storm” for type 1 diabetes: The complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes. 200857:2555-62.
• Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Ma-claren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest. 1994;94:2125.
• Gerstein HC. Cow’s milk exposure and type I diabetes mellitus. A critical overview of the clinical literature. Diabetes Care. 1994;17:13-9.
• Adler K, Mueller DB, Achenbach P, Krause S, Heninger AK, Ziegler AG, et al. Insulin autoantibodies with high affinity to the bovine milk protein a casein. Clin Exp Immunol. 2011;164:42-9.
• Norris JM, Barriga K, Klingensmith G, Hoffman M, Eisenbarth GS, Er-lich HA, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA. 2003;290:1713.
• Frederiksen B, Kroehl M, Lamb MM, Infant exposures and development of type 1 diabetes mellitus: The Diabetes Autoimmunity Study in the Young (DAISY). JAMA Pediatr. 2013;167:808.
• Norris JM, Yin X, Lamb MM, Barriga K, Seifert J, Hoffman M, et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA. 2007;298:1420.
• DeFronzo RA, Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and athe-rosclerotic cardiovascular disease. Diabetes Care. 1991;14:173.
• Beck-Nielsen H, Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. J Clin Invest. 1994;94:1714.
• Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: a cri-tical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Me-tab. 2004;89:3629.
• Gurlo T, Ryazantsev S, Huang CJ, Yeh MW, Reber HA, Hines OJ, et al. Evidence for proteotoxicity in beta cells in type 2 diabetes: toxic islet amyloid polypeptide oligomers form intracellularly in the secretory pathway. Am J Pathol. 2010;176:861
• Klein BE, Klein R, Moss SE, Cruickshanks KJ. Parental history of diabe-tes in a population-based study. Diabetes Care. 1996;19:827.
• Diabetes Genetics Initiative of Broad Institute of Harvard and MIT, Lund University, and Novartis Institutes of BioMedical Research, Saxena R, Voight BF, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide asso-ciation analysis identifies loci for type 2 diabetes and triglyceride levels. Science. 2007;316:1331.
• Scott LJ, Mohlke KL, Bonnycastle LL, Willer CJ, Li Y, Duren WL, et al. A genome-wide association study of type 2 diabetes in Finns detects mul-tiple susceptibility variants. Science. 2007;316:1341.
• Zeggini E, Weedon MN, Lindgren CM, Frayling TM, Elliott KS, Lango H, et al. Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes. Science. 2007; 316:1336.
• Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793.
• Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes. 2003;52:1799.
• Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM, et al. C-reacti-ve protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327.
• Niswender KD, Magnuson MA. Obesity and the beta cell: lessons from leptin. J Clin Invest. 2007;117:2753.
• Wannamethee SG, Whincup PH, Lennon L, Sattar N. Circulating adi-ponectin levels and mortality in elderly men with and without cardiovas-cular disease and heart failure. Arch Intern Med. 2007;167:1510.
• Laughlin GA, Barrett-Connor E, May S, Langenberg C. Association of adiponectin with coronary heart disease and mortality: the Rancho Ber-nardo study. Am J Epidemiol. 2007;165:164.
• Phillips DI, Barker DJ, Hales CN, Hirst S, Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia. 1994;37:150.
• Phillips DI, Hirst S, Clark PM, Hales CN, Osmond C. Fetal growth and insulin secretion in adult life. Diabetologia. 1994;37:592.
• Forsén T, Eriksson J, Tuomilehto J, Reunanen A, Osmond C, Barker D. The fetal and childhood growth of persons who develop type 2 diabetes. Ann Intern Med. 2000;133:176.
• Bhargava SK, Sachdev HS, Fall CH, Osmond C, Lakshmy R, Barker DJ, et al. Relation of serial changes in childhood body-mass index to impaired glucose tolerance in young adulthood. N Engl J Med. 2004;350:865.
• Dyck RF, Klomp H, Tan L. From “thrifty genotype” to “hefty fetal phe-notype”: the relationship between high birthweight and diabetes in Sas-katchewan Registered Indians. Can J Public Health. 2001;92:340.
• Sobngwi E, Boudou P, Mauvais-Jarvis F, Leblanc H, Velho G, Vexiau P, et al. Effect of a diabetic environment in utero on predisposition to type 2 diabetes. Lancet. 2003;361:1861.
• Murphy R, Ellard S, Hattersley A. Clinical implications of a molecular genetic classification of monogenic `-cell diabetes. Nat Clin Pract Endoc. 2008;4:200-13.
• Stride A, Vaxillaire M, Tuomi T, Barbetti F, NjØlstad PR, Hansen T, et al. The genetic abnormality in the beta cell determines the response to an oral glucose load. Diabetologia. 2012;45:427-35.
• Steele AM, Wensley KJ, Ellard E, Murphy R, Shepherd M, Colclough K, et al. Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: Observational case control studies. PLoS One. 2013;8:e65326.
• Colomand C, Corcoy R. Maturity onset diabetes of the Young and pregnancy Best Pract Res Clin Endocrinol. Metab. 2010;24:605-15.
• Stoffel M, Duncan SA. The maturity-onset diabetes of the Young (MODY 1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Prc Natl Acad Sci USA. 1997;94:13209-14.
• Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the Young. N Eng J Med. 2001;354:971-80.
• Stride A, Ellard S, Clark P, Shakespeare L, Salzmann M, Shepherd M, et al. `-cell dysfunction, insulin sensitivy, and glycosuria precede diabetes in hepatocyte nuclear factor-1_ mutation carriers. Diabetes Care. 2005;28:1751-6.
• Edghill EL, Bingham C, Ellard S, Hattersley AT. Mutations in hepatocy-te nuclear factor-1` and their related phenotypes. J Med Genet. 2006;43:84-90.
• Temple IK, Gardner RJ, Mackay DJG, Barber JCK, Robinson DO, Shield JPH. Transient neonatal diabetes: Widening the understanding of the etiopathogenesis of diabetes. Diabetes. 2000;49:1359-66.
• Flanagan SE, Patch AM, Mackay DJG, Edghill EL, Gloyn AL, Robinson D, et al. Mutations in ATP-sensitive K+ cannel genes cause transient neo-natal diabetes and permanente diabetes in childhood or adulthood. Dia-betes. 2007;56:1930-7.
• Pearson ER, Flechtner I, NjØlstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with dia-betes due to Kir6.2 mutations. N Engl J Med. 2006;355:467-77.
• Hattersley AT, Ascroft FM. Activating mutations in Kir6.2 and neonatal diabetes: New clinical síndromes, new scientific insights, and new thera-py. Diabetes. 2005; 54:2503-13.
• Slingerland AS, Hurkx W, Noordamet K, Flanagan SE, Jukema JW, Mei-ners LC, et al. Sulphonylurea therapy improves cognition in a patient with the V59M KCNJ11 mutation. Diabetic Med. 2008;25:277-81.
• Moran A, Doherty L, Wang X, Thomas W. Abnormal glucose metabo-lism in cystic fibrosis. J Pediatr. 1998;133:10.
• Bismuth E, Laborde K, Taupin P, Velho G, Ribault V, Jennane F, et al. Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis. J Pediatr. 2008;152:540.
• Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ. Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration. 2008;76:181.
• Nousia-Arvanitakis S, Galli-Tsinopoulou A, Karamouzis M. Insulin im-proves clinical status of patients with cystic-fibrosis-related diabetes me-llitus. Acta Paediatr. 2001;90:515.
• Yaouanq JM. Diabetes and haemochromatosis: current concepts, mana-gement and prevention. Diabete Metab. 1995;21:319.
• Utzschneider KM, Kowdley KV. Hereditary hemochromatosis and dia-betes mellitus: implications for clinical practice. Nat Rev Endocrinol. 2010;6:26.